ENVERIC BIOSCIENCES INC (ENVB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.39-3.47%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ENVB
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||||
| Revenues | — | — | — | — | — | — | — | 39.9 | 43.0 | 48.6 | 36.1 | — | — | — | — |
| Total Revenues | — | — | — | — | — | — | — | 39.9 | 43.0 | 48.6 | 36.1 | — | — | — | — |
| Cost of Revenues | — | — | — | — | — | — | — | 31.8 | 34.0 | 38.4 | 29.2 | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | 8.2 | 9.0 | 10.2 | 6.9 | — | — | — | — |
| Operating Expenses & Income | |||||||||||||||
| Selling, General & Admin | — | — | — | — | — | 20.5 | 5.3 | 2.3 | 10.8 | 18.5 | — | — | — | — | — |
| R&D Expenses | 2.5 | 2.8 | 2.8 | 7.3 | 8.0 | 4.8 | 0.2 | — | — | — | 0.1 | — | — | — | — |
| Operating Income | (8.7) | (8.8) | (9.6) | (16.4) | (27.4) | (64.6) | (5.6) | (2.3) | (7.1) | (10.9) | (5.4) | 0.0 | 0.0 | (0.0) | (0.0) |
| Earnings from Continuing Operations | |||||||||||||||
| Interest Expense | — | — | — | — | 0.0 | 0.0 | 0.4 | 0.1 | 0.7 | 0.6 | 0.8 | — | — | — | — |
| Other Non-Operating Income / Expenses | (0.0) | 0.0 | 0.1 | (0.8) | 7.5 | 8.2 | (1.2) | 0.1 | (3.4) | (0.6) | (1.1) | — | — | — | — |
| Asset Writedown | — | — | — | — | 6.0 | 29.0 | — | — | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | (8.7) | (8.8) | (9.6) | (17.3) | (20.0) | (56.4) | (6.9) | (5.2) | (10.5) | (11.5) | — | (0.0) | 0.0 | (0.0) | (0.0) |
| Income Tax Expense | — | — | 0.0 | 0.0 | (1.5) | (7.5) | — | 0.4 | 6.3 | (2.4) | (3.7) | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | |||||||||||||||
| Minority Interest | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | — | — | — | — |
| Net Income | 12.1 | (8.8) | (9.6) | 17.5 | (18.5) | (49.0) | (6.9) | (2.4) | (16.9) | (9.1) | (2.8) | (0.0) | (0.0) | (0.0) | (0.0) |
| Per Share | |||||||||||||||
| Basic EPS | 3.05 | (36.24) | (19.04) | (121.29) | (13.00) | (103.69) | — | (2.83) | (20.47) | (0.75) | (0.21) | — | — | — | — |
| Diluted EPS | 3.05 | (36.24) | (19.04) | (121.29) | (13.00) | — | — | (2.83) | (20.47) | (0.75) | (0.21) | — | — | — | — |
| Basic Weighted Avg Shares | 4.0 | 0.3 | 0.5 | 0.1 | 1.4 | 0.5 | 5.8 | 5.3 | 1.0 | 15.0 | 13.1 | 15.2 | 12.1 | 12.1 | 8.5 |
| Diluted Weighted Avg Shares | 4.0 | 0.3 | 0.5 | 0.1 | 1.4 | — | — | 2.1 | 1.0 | 15.0 | 13.1 | — | — | — | — |
| Supplemental | |||||||||||||||
| EBITDA | — | (8.6) | (9.3) | (16.1) | (27.1) | (64.0) | (5.5) | (0.0) | (4.2) | (7.7) | (4.0) | — | — | — | — |
| EBIT | (8.7) | (8.8) | (9.6) | (16.4) | (27.4) | (64.6) | (5.6) | (2.3) | (7.1) | (10.9) | (5.4) | 0.0 | 0.0 | (0.0) | (0.0) |
| Effective Tax Rate | — | — | — | -0.2% | 7.4% | 13.2% | — | -7.4% | -60.2% | 20.9% | — | -2.5% | 112.5% | -8.5% | -6.3% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.